论文部分内容阅读
目的 观察负载妥布霉素的硫酸钙(Osteoset-T)治疗老年慢性骨髓炎的临床疗效及安全性.方法 将52例老年慢性骨髓炎患者随机分为对照组26例和试验组26例.2组患者均予以清创手术治疗,在此基础上,对照组予以庆大霉素骨水泥(4 mg·g-1)填塞清创后空腔,试验组予以Osteoset-T(4％妥布霉素)填塞清创后空腔.2组患者均治疗7d.比较2组患者的临床疗效、血清溶菌酶(LZM)、C反应蛋白(CRP)、以及药物不良反应的发生情况.结果 治疗后,试验组和对照组的总有效率分别为88.46％(23/26例)和65.38％(17/26例),差异有统计学意义(P＜0.05).治疗后,试验组和对照组的LZM分别为(22.45±1.78),(18.54±1.32)μg·L-1;CRP分别为(1.58±0.22),(3.86±0.43)mg·L-1,差异均有统计学意义(均P ＜0.05).试验组发生局部渗液,对照组发生局部渗液和伤口愈合延迟.试验组和对照组的药物不良反应的发生率分别为3.85％和7.69％,差异无统计学意义(P＞0.05).结论 Osteoset-T治疗老年慢性骨髓炎的临床疗效显著,其能显著提高患者的血清LZM水平,降低血清CRP水平,且不增加药物不良反应的发生率.“,”Objective To observe the clinical efficacy and safety of Osteoset-T in the treatment of elderly patients with chronic osteomyelitis.Methods A total of 58 elderly patients with chronic osteomyelitis were randomly divided into control group and treatment group with 26 cases per group.Two groups were treated with debridement.After debridement,control group was given gentamicin bone cement (4 mg · g-1) filling the cavity,the treatment group was given Osteoset-T (4％ Tobramycin)filling the cavity.The clinical efficacy,lysozyme (LZM),C reactive protein (CRP) and adverse drug reactions were compared between the two groups.Results After treatment,the total effective rates in treatment and control groups were 88.46％ (23/26 cases) and 65.38％ (17/26 cases) with significant difference (P ＜ 0.05).After treatment,LZM in treatment and control groups were (22.45 ± 1.78),(18.54 ±1.32) μg · L-1;CRP in treatment and control groups were (1.58 ± 0.22),(3.86 ± 0.43) mg · L-1,with significant differences (P ＜ 0.05).The adverse drug reactions in treatment group were local infiltration fluid,which in control group were local infiltration fluid and delayed wound healing.The incidences of adverse drug reactions in treatment and control groups were 3.85％ and 7.69％ without significant difference (P ＞0.05).Conclusion Osteoset-T has a definitive clinical efficacy in the treatment of elderly patients with chronic osteomyelitis,which can improve the levels of LZM,reduce the levels of CRP,without increasing the incidence of adverse drug reactions.